Global biotech firms Oncopeptides AB (pub) (Nasdaq Stockholm: ONCO) have announced today that companies have sent a submission to the EU for the conditional marketing approval of a pivotal Phase 2 HORIZON-based melflufen trial for the treatment of haematologically difficult diseases 996 casino (HDCs) (melphalan fluperamide) Without positive EMA confirmation, melflufen are going to be […]